Orchestra BioMed
OBIO
54 hedge funds and large institutions have $77M invested in Orchestra BioMed in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 4 closing their positions.
271% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 7
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
13% more funds holding
Funds holding: 48 → 54 (+6)
0.35% more ownership
Funds ownership: 50.29% → 50.65% (+0.35%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $97.8M → $77M (-$20.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$207K |
| 2 |
BlackRock
New York
|
+$196K |
| 3 |
Millennium Management
New York
|
+$116K |
| 4 |
Goldman Sachs
New York
|
+$108K |
| 5 |
State Street
Boston,
Massachusetts
|
+$97.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$137K |
| 2 |
Jane Street
New York
|
-$98K |
| 3 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
-$63K |
| 4 |
Morgan Stanley
New York
|
-$42.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$42.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
Sierra Ocean
Ripon,
California
| $476 | +$639 | +119 | New |
|
52
Nisa Investment Advisors
St. Louis,
Missouri
| $288 | +$11 | +2 | +3% |
|
|
SS
53
SBI Securities
Tokyo,
Japan
| $4 | +$5 | +1 | New |
|
|
BC
54
Boxer Capital
San Diego,
California
| – | -$1.22M | -238,193 | Closed |
|
|
55
Jane Street
New York
| – | -$98K | -19,070 | Closed |
|
|
SIA
56
SkyView Investment Advisors
Shrewsbury,
New Jersey
| – | -$63K | -12,284 | Closed |
|
|
CPA
57
Capital Performance Advisors
Walnut Creek,
California
| – | -$41 | -8 | Closed |
|
58
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$11 | +2 | +25% |
|
OBIO Hedge Fund Activity: Q4 2024 in Review
54 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2024, worth a combined $77M — down 21% from $97.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OBIO positions and 4 closed out — a net gain of 6 holders — while 26 added to existing stakes and 7 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $207K. The largest seller was T. Rowe Price Associates, cutting an estimated $137K.
- 54 institutional investors held Orchestra BioMed (OBIO) as of Q4 2024, up from 48 in Q3 2024.
- Funds reported $77M of Orchestra BioMed stock for Q4 2024, down 21% quarter-over-quarter.
- 10 funds opened new Orchestra BioMed positions in Q4 2024 and 4 closed out, a net change of +6 holders.
- The largest Orchestra BioMed buyer in Q4 2024 was JP Morgan Chase, an estimated $207K added.
- The largest Orchestra BioMed seller in Q4 2024 was T. Rowe Price Associates, an estimated $137K sold.
Based on aggregated 13F filings for Q4 2024.